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The host response to viral infection involves the secre-
tion of multiple cytokines which alter immune function
and viral replication. These proteins activate several
signal transduction pathways in infected cells which
must be integrated to regulate cellular and viral gene
expression. In this report, we demonstrate that specific
transcription factors induced by distinct cytokines
regulate HIV transcription by competitive binding to
the p300 coactivator. Interferon-α (IFN-α) was found
to inhibit NF-κB-dependent HIV gene expression
stimulated by tumor necrosis factor-α (TNF-α). This
inhibition was mediated by binding of the IFN-α signal
transducer and activator of transcription 2, Stat2, to
a specific domain of p300 which also binds to the RelA
(p65) subunit of NF-κB. p300 was found to be limiting
with respect to RelA (p65) and Stat2, and this effect
was reversed by overexpression of p300. Inhibition by
Stat2 was specific for NF-κB and was not mediated by
Stat1, which is also induced by IFN-α. Gene activation
induced by the Stat2 transcription domain was also
inhibited by expression of RelA. These results demon-
strate that HIV transcription can be regulated in the
nucleus by competitive binding of specific cytokine-




The activation of gene expression by cytokines results in
activation of transcription factors which exert diverse
effects on cellular genes (for reviews see Hill and
Treisman, 1995; Marshall, 1995). The cytokines
interferon-α (IFN-α) and tumor necrosis factor-α (TNF-α)
represent mediators often released during immune and
inflammatory responses that stimulate different patterns
of cellular and viral gene expression. IFN-α inhibits the
replication of many viruses (Dorr, 1993), including the
human immunodeficiency virus (HIV) (Yamada et al.,
1988; Fan et al., 1993; Bourinbaiar et al., 1995), for
example, while TNF-α enhances HIV-1 transcription
through induction of NF-κB which binds to two κB
sites within the long terminal repeat (LTR) (Nabel and
Baltimore, 1987). Recently, NF-κB transcriptional activity
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was shown to be regulated by the activity of cyclin-
dependent kinases (Cdks) through the p300 or the CREB-
binding protein (CBP) coactivators (Perkins et al., 1997).
The binding of the RelA (p65) subunit of NF-κB to p300/
CBP was found to be mediated through the N-terminal
region of p300, while cyclin E–Cdk2 interacted with the
C-terminus. CBP was identified originally in a screening
approach as a protein which interacted strongly with
CREB (Chrivia et al., 1993; Kwok et al., 1994), and p300,
which is highly related to CBP, was found based on its
interaction with E1A (Eckner et al., 1994).
Both molecules are large nuclear phosphoproteins that
appear to be involved in the regulation of cellular growth
control (Eckner, 1996) and were also proposed to be
critical for integration and regulation of different pathways,
such as the inhibitory actions of the glucocorticoid receptor
and the retinoic acid receptor on AP-1 activation (Kamei
et al., 1996) or the nuclear signaling of the JAK/STAT
and the Ras/AP-1 pathway (Horvai et al., 1997). It was
reported recently that p300/CBP not only interacts with a
histone acetyltransferase (P/CAF; Yang et al., 1996) but
also itself possesses an intrinsic histone acetyltransferase
activity (Bannister and Kouzarides, 1996; Ogryzko et al.,
1996) and may therefore not only be an adaptor between
DNA-binding factors and P/CAF but may also contribute
directly to transcriptional regulation via targeted
acetylation of chromatin. Interestingly, p300/CBP appears
to be a molecule that is a point of conversion for viral
proteins as well as for cellular signal transduction pathways
(Nakajima et al., 1996; Torchia et al., 1997). In addition,
p300 regulates a variety of transcription factors unrelated
to NF-κB, including p53 (Lee et al., 1995; Gu et al.,
1997; Lill et al., 1997a) Myb (Dai et al., 1996;
Oelgeschlager et al., 1996), Jun (Bannister et al., 1995),
Fos (Bannister and Kouzarides, 1995), Sap1a (Janknecht
and Nordheim, 1996), Stat1 (Zhang et al., 1996), Stat2
(Bhattacharya et al., 1996), myogenic transcription factors
(Eckner, 1996; Yuan et al., 1996) and nuclear receptors
(Kamei et al., 1996; for reviews, see Eckner, 1996;
Janknecht and Hunter, 1996; Shikama et al., 1997). Among
these factors, the Stat2 protein induced by IFN-α as part
of the ISGF-3 complex (Schindler and Darnell, 1995)
binds to an N-terminal region of p300 in proximity to the
RelA site that is distinct from that bound by other
factors such as CREB, c-Jun, c-Myb, SAP-1 and YY1
(Bhattacharya et al., 1996; Eckner, 1996). This observation
raised the possibility of competitive interactions among
specific transcription factors to regulate gene expression
induced by multiple signal transduction pathways, such
as the inhibitory activity of IFN-α on the TNF-α-induced
transcriptional activation of the HIV-1 LTR. In support of
this possibility, we demonstrate that RelA and Stat2 can
compete directly for p300 binding and, remarkably, that
this competition dramatically influences transcriptional
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Fig. 1. Common binding domain and competition of RelA and Stat2 binding to p300. (A) RelA binds p300 between amino acid residues 1 and 610.
RelA was immunoprecipitated from nuclear extracts of 293 cells which express transfected RelA and incubated with radiolabeled in vitro translated
N-terminal deletion mutants of p300 (lanes 2, 4, 6 and 8, designated ). After three washes, bound proteins were resolved by SDS–PAGE. A non-
specific rabbit IgG was included as a negative control (lanes 1, 3, 5 and 7, designated C). (B) RelA and Stat2 bind to the CH1 region on p300.
Approximately 100 ng of GST–p300 (CH1) fusion protein was pre-bound to glutathione-conjugated agarose beads (lanes 3 and 6) and incubated
with the radiolabeled in vitro translated transactivation domain of Stat2 (amino acids 670–851, left panel) or RelA (right panel). Purified GST was
included as control (lanes 2 and 5). After washing, bound protein was resolved by SDS–PAGE. The lane designated ‘Input’ represents 10% of the
input protein. (C) Competitive binding of Stat2 and RelA to p300 (CH1). Proteins from Jurkat nuclear extracts were immunoprecipitated with a
control antibody (lane 2) or an antibody to p300 (lanes 3–5) and incubated with in vitro translated full-length RelA in the presence of GST–
Stat2(TA) (lane 3) or a GST–Stat2(TA)ΔC control (lane 4). After washing, bound complexes were resolved by SDS–PAGE. Lane 1 contains 10% of
the input protein. (D) RelA and Stat2 do not interact directly. In vitro co-translated RelA and Stat2 were immunoprecipitated with a control rabbit
IgG (lane 2), an anti-RelA IgG (lane 3) or an anti-Stat2 IgG (lane 4). Under the same conditions, in vitro co-translated RelA and p50 were
immunoprecipitated with a control rabbit IgG (lane 6) and anti-RelA IgG (lane 7). The lanes designated 1 and 5 represent 10% of the in vitro
translated input protein.
activation of the HIV-1 LTR. Through this mechanism,
p300 may regulate viral gene expression in the setting of
simultaneously activated signal transduction pathways.
Results
Binding of RelA and Stat2 to the p300 CH1 domain
and competition studies
To examine possible regulatory mechanisms that coordinate
diverse signal transduction pathways, we investigated
whether Stat2 and RelA might bind to the same region
of p300. Incubation of 5 deletion mutants of p300 with
immunoprecipitated RelA revealed a region of p300
between amino acids 1 and 610 that was responsible for
RelA binding (Figure 1A). Similar results were obtained
for the transcription factor Stat2 (data not shown). This
fragment contains a cysteine–histidine-rich region of p300,
the CH1 domain (amino acids 302–442). An overlapping
region (amino acids 300–528) has been shown previously
to bind to Stat2 (Bhattacharya et al., 1996). To localize the
binding region for these proteins further, a GST–CH1 fusion
protein (amino acids 302–422) was prepared and incubated
with in vitro translated RelA or the transactivation domain
of Stat2 (amino acids 670–851). This CH1 domain was
necessary and sufficient for specific binding of Stat2 or
RelA to p300 (Figure 1B), though additional non-specific
binding to other regions of p300 or CBP cannot be excluded.
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To determine whether the Stat2 and RelA transcriptional
activation domains could bind competitively to this region
of p300, competition experiments were performed. GST–
Stat2(TA), which contains the transactivation domain of
Stat2 (amino acids 670–851) fused to GST, reduced the
binding of RelA to p300 to background levels compared
with a control GST–Stat2(TA)ΔC fusion protein which
lacked the C-terminal 83 amino acids (Figure 1C). This
finding indicated that Stat2 competes with RelA for binding
to p300 and that the C-terminal 83 amino acids which
mediate binding of Stat2 to p300 (Bhattacharya et al., 1996)
are required for this competition. To exclude further the
possibility that Stat2 could interact directly with RelA and
thereby inhibit RelA binding to p300, we performed in vitro
immunoprecipitations using the same buffer conditions as
for Figure 1C. In vitro translated RelA and Stat2 did not
co-associate in immunoprecipitation assays, indicating that
RelA and Stat2 do not interact directly, whereas RelA under
the same conditions interacted with p50 to form the expected
heterodimer (Figure 1D).
Inhibition of TNF-α-stimulated NF-κB transcription
by IFN-α
To determine whether endogenous Stat2 induced by IFN-α
can inhibit TNF-α induction of endogenous NF-κB and
its subsequent gene activation through this regulatory
mechanism in the nucleus, cytokine stimulation studies
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Fig. 2. IFN-α inhibits TNF-α-induced HIV-1 gene expression in a
κB-dependent manner. The specificity of IFN-α inhibition for a
κB-dependent reporter. Jurkat T-leukemia cells were transfected with
μg of HIV CAT or 5 μg of ΔκB-HIV CAT (A) or RSV–CAT (B) and
pre-stimulated with 1000 U/ml IFN-α for 20 h followed by TNF-α
stimulation (20 U/ml) for 4 h in (A) or stimulated for 20 h with
1000 U/ml IFN-α in (B). Error bars indicate SEM of three
independent experiments.
were performed. Jurkat T-leukemia cells were transfected
with an HIV–CAT reporter and incubated with IFN-α
before adding a constant amount of TNF-α 20 h later.
IFN-α inhibited κB-dependent CAT activity stimulated by
TNF-α (Figure 2A), whereas no transcriptional activation
of HIV–CAT was observed by IFN-α itself. No inhibitory
effect of IFN-α could be observed in transfection assays
with the relevant control (mutant κB) reporter plasmid,
indicating that the observed inhibitory effect was depend-
ent on NF-κB (Figure 2A). Identical treatment of Jurkat
cells transfected with a Rous sarcoma virus (RSV)–
CAT plasmid, which expresses CAT constitutively and
independently of NF-κB, showed no difference in CAT
activity (Figure 2B), indicating that this effect was specific
for NF-κB and did not affect the activity of basal transcrip-
tion factors.
IFN-α but not IFN-γ is able to inhibit RelA
transactivation: lack of Stat1 involvement
IFN-α not only modifies Stat2 but also induces nuclear
translocation of Stat1 as part of the ISGF-3 complex
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Fig. 3. IFN-γ does not inhibit TNF-α-induced HIV-1 gene expression.
(A) IFN-γ does not affect κB-dependent gene activation. Jurkat
T-leukemia cells were transfected with HIV–CAT (5 μg) and pre-
stimulated with 1000 U/ml of IFN-γ for 20 h followed by TNF-α
stimulation (20 U/ml) for 4 h. Error bars indicate SEM of three
independent experiments. (B and C) Specific transcriptional activation
by IFN-α and IFN-γ on different reporter plasmids. Jurkat T-leukemia
cells were transfected with α-IRE-CAT (5 μg; B) or GAS/α-IRE–CAT
(5 μg; C) reporter plasmid and subsequently stimulated with 100 U/ml
of IFN-α or IFN-γ for 20 h. Error bars indicate SEM of three
independent experiments.
(Schindler and Darnell, 1995). Stat1 has been shown to
interact with p300, but its potential effects on RelA-
mediated transaction through p300 have not been defined.
To address whether Stat1 may affect p300-dependent
NF-κB transcriptional activation, cells were stimulated
with IFN-γ which causes nuclear translocation of Stat1
but not Stat2 (Schindler and Darnell, 1995), and its effect
on TNF-α-induced NF-κB activity was determined. IFN-γ
did not inhibit κB-dependent transcription stimulated by
TNF-α, and no transcriptional activation of HIV–CAT
was observed by IFN-γ itself (Figure 3A). This result
excluded the possibility that Stat1 served as the competing
molecule induced by IFN-α, and further suggested that
Stat2 was required for competition with NF-κB. The
presence of a functional IFN-γ receptor and Stat1 in Jurkat
cells was confirmed with two different CAT reporter
plasmids under the transcriptional control of different
elements, a gamma-activated sequence (GAS) element,
recognized by the Stat1 homodimer induced by IFN-γ, or
an α-interferon-responsive element (α-IRE) regulated by
the ISGF-3 trimer complex induced by IFN-α. α-IRE–
CAT activity could be stimulated only by IFN-α, whereas
the plasmid containing the α-IRE plus two GAS elements
could be activated by either IFN-α or IFN-γ (Figure 3B
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Fig. 4. Lack of IFN-α effect on nuclear translocation and induction of
NF-κB DNA-binding activity, and RelA and Stat2 do not interact
in vivo. (A) IFN-α has no effect on the nuclear translocation of the
NF-κB subunit RelA. Western blot analysis of Jurkat T-leukemia cells
which were unstimulated (lane 1), or stimulated with 20 U/ml TNF-α
(lane 2) or 100 U/ml TNF-α for 4 h (lane 3), stimulated with
1000 U/ml IFN-α for 20 h (lanes 4), or stimulated with 1000 U/ml
IFN-α for 20 h, followed by a stimulation with 20 U/ml TNF-α (lane
5) or 100 U/ml TNF-α for 4 h (lane 6). The upper panel shows the
analysis for p300, the middle panel the analysis for Stat2, and the
lower panel the analysis for RelA. For each lane, 30 μg of nuclear
extracts were used. (B) IFN-α does not affect the NF-κB
DNA-binding activity. EMSA of nuclear extracts from Jurkat cells
unstimulated (lanes 1–3), stimulated with 1000 U/ml IFN-α for 20 h
(lanes 10–12), stimulated with 20 U/ml TNF-α for 4 h (lanes 4–6) or
stimulated with 1000 U/ml IFN-α, followed by a stimulation with
20 U/ml TNF-α for 4 h (lanes 7–9). (C) RelA and Stat2 do not
interact in vivo. RelA induced by TNF-α (100 U/ml; for 4 h) and
Stat2 induced by IFN-α (1000 U/ml; for 20 h) were
immunoprecipitated with a control rabbit IgG (lane 2), an anti-RelA
IgG (lane 3) or an anti-Stat2 IgG (lane 4). Lane 1 represents 20 μg of
nuclear extract.
and C), thus confirming that both transcriptional activators
were induced appropriately by IFN-α or IFN-γ in these
cells, though only IFN-α, which induced Stat2, affected
NF-κB/p300 binding.
Lack of IFN-α effect on the induction of RelA and
NF-κB DNA-binding activity
TNF-α has been shown to induce NF-κB through its
ability to activate the degradation of the inhibitory protein
family IκB which sequesters NF-κB in the cytoplasm
(Beg and Baldwin, 1993; Baeuerle and Henkel, 1994). To
exclude the possibility that IFN-α could interfere with
the TNF-α signal transduction pathway which causes
degradation of IκB and liberation of NF-κB for nuclear
import, we examined the amount of NF-κB translocated
into the nucleus after TNF-α, or TNF-α plus IFN-α,
treatment. Western blot analyses of nuclear RelA, Stat2,
and p300 were performed (Figure 4A). The level of p300
was not affected by the treatment of cells with TNF-α or
IFN-α, and the level of RelA was also unaffected by pre-
treatment of cells with IFN-α. The electrophoretic mobility
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shift assay (EMSA) was performed with nuclear extracts
of the relevant cytokine-treated cells. This analysis
revealed that NF-κB induction was not affected by pre-
stimulation with IFN-α (Figure 4B), suggesting that
TNF-α receptor function was intact in cells treated with
IFN-α and that the mechanism of IFN-α inhibition of
NF-κB did not involve degradation of IκB.
RelA and Stat2 do not interact in vivo
To exclude the possibility that Stat2 could interact with
RelA in vivo and thereby influence the transcriptional
activation by RelA, we performed an immunoprecipitation
study. Immunoprecipitation of RelA or Stat2 from nuclear
proteins after extraction of Jurkat cells stimulated with
IFN-α and TNF-α showed no interaction between the two
transcription factors (Figure 4C). This observation suggests
that RelA and Stat2 interact with one another neither
directly nor indirectly through p300. Analysis of competi-
tion between endogenous RelA and Stat2 for binding to
p300 after cytokine treatment was not possible in vivo
since the high salt concentration required for nuclear
extract preparation disrupts the physiologic interactions
of these proteins.
Inhibition of NF-κB or Stat2 transcription by the
relevant counter-active cytokine or transcriptional
activation domain
To confirm the physiological relevance of this interaction,
we analyzed the effects of IFN-α and TNF-α, which
induce the Stat2 and RelA transcription factors, respect-
ively, through their relevant cellular cytokine receptors.
Transfected RelA inhibited transcriptional activation of a
CAT reporter containing a regulatory region from the 2–
5 oligo adenylate synthetase (OAS) gene that is regulated
by IFN-α (Figure 5A). Conversely, TNF-α activation of
the HIV-1 enhancer by NF-κB was inhibited by an
expression vector encoding a GAL4 fusion protein linked
to the Stat2 transactivation domain [GAL4–Stat2(TA)],
but not by GAL4–Stat2(TA)ΔC which lacked the
C-terminal 83 amino acids (Figure 5B). When transfection
of an expression vector encoding RelA was used to
activate NF-κB gene expression, incubation with IFN-α,
which induced Stat2 physiologically, exerted a similar
inhibitory effect (Figure 5C). No inhibitory effect of
GAL4–Stat2(TA) or IFN-α could be observed in transfec-
tion assays with the relevant control (mutant κB) reporter
plasmid, indicating that the observed inhibitory effect was
dependent on NF-κB (data not shown). Taken together,
these results suggest that physiologically induced Stat2
can negatively regulate the transcriptional activity of RelA
and vice versa, and that these effects are mediated through
the transcriptional activation domains of each protein.
Competition by Stat2 and RelA for binding to p300
in vivo
The functional interaction of these proteins was demon-
strated in vivo by transient transfection assays. Transfected
RelA (Figure 6A) inhibited transcriptional activation by
GAL4–Stat2(TA) on a GAL4 reporter plasmid. Con-
versely, co-transfections were performed with HIV–CAT
and GAL4–Stat2(TA). GAL4–Stat2(TA) strongly inhibited
HIV enhancer activation by transfected RelA, whereas
GAL4–Stat2(TA)ΔC alone had no effect (Figure 6B). No
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Fig. 5. Physiologically induced or transfected Stat2 or RelA cross-
inhibit gene activation. (A) Transfection of an expression vector
encoding RelA is sufficient to inhibit IFN-α-dependent gene
activation. Jurkat cells were transfected with OAS–CAT (2 μg) and 2
or 6 μg of RelA expression plasmid. After 20 h, cells were stimulated
with IFN-α (200 U/ml) for 16 h. A control vector with the same RSV
regulatory region was included such that a total of 6 μg of RelA and
control plasmids was present per sample. (B) Transfection of an
expression vector encoding the transactivation domain of Stat2 is
sufficient to inhibit RelA-dependent gene activation. Jurkat cells were
transfected with HIV–CAT (5 μg) and GAL4–Stat2(TA) (2 μg) or
GAL4–Stat2(TA)ΔC (2 μg) as indicated. After 20 h, cells were
stimulated with TNF-α (20 U/ml) for 4 h. A control vector with the
same RSV regulatory region was included such that a total of 2 μg of
the GAL4–Stat2(TA) and control plasmids was present per sample.
Error bars indicate SEM of three independent experiments. (C) Jurkat
T-leukemia cells were transfected with 0.1 μg of RSV expression
plasmids encoding RelA and HIV–CAT (5 μg). A control plasmid was
included so that each sample contained a total of 0.4 μg of RSV
expression plasmid. Cells were stimulated for 24 h with 1000 U/ml of
IFN-α and harvested. Error bars indicate SEM of three independent
experiments.
inhibition was seen with a control plasmid with mutated
κB sites (data not shown). If competitive binding of Stat2
to p300 was responsible for this inhibitory effect rather
than a general non-specific squelching effect which is
particularly pronounced on unintegrated episomal reporter
genes (Natesan et al., 1997), it would be predicted
that transfection of p300 should restore RelA-dependent
activation in the presence of GAL4–Stat2(TA). Co-trans-
fection of p300 with HIV–CAT, RelA and GAL4–
Stat2(TA) indeed restored HIV enhancer activity 5-fold
(Figure 6C). The comparison of the sample with RelA
alone and RelA plus p300 did not show significant
differences, in contrast to our previous study (Perkins
et al., 1997), because the amount of transfected p300
plasmid used in Figure 6C was suboptimal for trans-
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Fig. 6. The transactivation domain of Stat2 competes with the NF-κB
subunit RelA for a limiting amount of p300 in vivo. (A) Gene
activation by the transactivation domain of Stat2 is inhibited by
transfection of a RelA expression vector. Jurkat cells were transfected
with 2 μg of GAL4–CAT reporter plasmid, 0.2 μg of GAL4–
Stat2(TA), and RelA as indicated. A control RSV vector was included
such that the same amount of plasmids was present per sample.
(B) Expression of transfected Stat2 represses RelA-mediated
transcriptional activation. Jurkat cells were co-transfected with HIV–
CAT (5 μg), GAL4–Stat2(TA) (2 μg) or GAL4–Stat2(TA)ΔC (2 μg),
and RSV–RelA (0.2 μg) as indicated. A control RSV vector was
included such that a total of 2 μg of expression plasmids was used in
each sample. Error bars indicate SEM of three independent
experiments. (C) Inhibition of transfected GAL4–Stat2(TA) by co-
transfected RelA is relieved by expression of p300. Jurkat cells were
transfected with HIV–CAT (2 μg), RSV–RelA (0.2 μg), GAL4–
Stat2(TA) (2 μg) and CMV-p300 expression vector (5 μg) as
indicated. A control CMV vector encoding alkaline phosphatase (AP)
was included as a control such that a total of 5 μg of the p300 and
control plasmids was present in each sample. Cells were harvested
after 48 h. Error bars indicate SEM of three independent experiments.
(D) Inhibition of transfected GAL4–Stat2(TA) by co-transfected RelA
is relieved by expression of the CH1 domain of p300. Jurkat cells
were transfected with HIV–CAT (2 μg), RSV–RelA (0.2 μg), GAL4–
Stat2(TA) (2 μg) and different p300 deletion mutants (5 μg) as
indicated. A control CMV vector encoding AP was included as a
control such that a total of 5 μg of the p300 and control plasmids was
present in each sample. Cells were harvested after 48 h. Error bars
indicate SEM of three independent experiments. (E) Western blot
analysis of RelA and GAL4–Stat2 from 293 cell nuclear extracts.
293 cells were transfected with 0.2 μg of GAL4–Stat2(TA) and 6 μg
of RelA, and subsequently analyzed for GAL4–Stat2 (left panel) or
transfected with RSV–RelA (0.2 μg) and GAL4–Stat2(TA) (2 μg)
(middle panel) or RSV-RelA (0.2 μg), GAL4–Stat2(TA) (2 μg) and
CMV-p300 expression vector (5 μg) (right panel) and analyzed for
RelA. All transfections contained a LacZ reporter to standardize the
loaded amount of proteins.
activation, thus simplifying the interpretation of the experi-
ment. To confirm that the CH1 domain of p300 is limiting,
another transfection experiment was performed with a
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deletion mutant of p300 which contains the CH1 domain
(amino acids 1–596) and a deletion mutant of p300 which
lacks the CH1 domain (amino acids 1–349). The (amino
acids 1–596) p300 mutant was able to restore the Stat2
repression in comparison with the mutant lacking CH1,
indicating that the CH1 domain is indeed the domain
responsible for the rescue of the repression in vivo
(Figure 6D). This observation excludes the possibility that
the Stat2 transactivation domain exerts a non-specific
effect and is consistent with the hypothesis that Stat2 and
RelA compete for binding to p300 in vivo. The CH1
p300 mutant showed some degree of activation by itself,
suggesting that it may bind other endogenous transcription
factors which can compete with RelA for binding to p300.
In addition, this result suggests that the presence and total
quantity of all p300/CBP family members in the cell
nucleus is not sufficient to overcome the inhibitory activa-
tion of Stat2 after overexpression or physiological induc-
tion by IFN-α. To exclude further the possibility that
the inhibitory effect of GAL4–Stat2 or RelA is due to
interference with the expression level after transfection,
we performed Western blot analysis with nuclear extract
from cells transfected with the same DNA combinations
as shown in Figure 6A–C. No significant difference in the
expression level of RelA or GAL4–Stat2 could be detected
(Figure 6D).
Inhibition of TNF-α-stimulated NF-κB transcription
by IFN-α is dose dependent, and the time course
of Stat2 induction and translocation by IFN-α
To determine whether IFN-α can inhibit TNF-α induction
of endogenous NF-κB in a dose-dependent manner, cyto-
kine stimulation studies were performed. Jurkat T-leukemia
cells were transfected with an HIV–CAT reporter and
incubated with increasing amounts of IFN-α before adding
a constant amount of TNF-α 20 h later. IFN-α inhibited
κB-dependent CAT activity stimulated by TNF-α in a
dose-dependent manner (Figure 7A). To confirm that the
IFN-α dose–response curve for inhibition of HIV–CAT
expression correlates with the dose–response relationship
for Stat2 activation, we performed an experiment using a
reporter plasmid containing the CAT gene regulated by
the α-IRE, which is activated by the Stat2-containing
ISGF-3 complex specifically induced by IFN-α (Figure
7B). The activation of the α-IRE–CAT reporter correlated
with the dose–response inhibition of HIV–CAT activity
(Figure 7A). To determine whether the inhibitory activity
of IFN-α on TNF-α-induced gene activation can be exerted
on a stably integrated gene, we repeated the cytokine
studies with the 1G5 cell line, which contains a stable
integrated luciferase gene under the control of the HIV-1
LTR (Aguilar-Cordova et al., 1994). 1G5 cells were
incubated with increasing amounts of IFN-α before adding
a constant amount of TNF-α 20 h later. IFN-α inhibited
κB-dependent luciferase activity stimulated by TNF-α in
a dose-dependent and saturable manner (Figure 7C).
Both for transient transfection and stably integrated κB
reporters, pre-incubation with IFN-α for at least 6 h was
required for significant inhibition of TNF-α-stimulated
NF-κB function (Figure 7D), indicating that cross-
signaling of rapidly activated cellular protein kinases by
these two pathways was unlikely. To understand the
quantitative aspects of Stat2 induction by IFN-α, we
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determined the kinetics of Stat2 nuclear localization after
IFN-α stimulation by exposure of Jurkat cells to this
cytokine for different time intervals. Stat2 began to trans-
locate to the nucleus shortly after stimulation with IFN-α
(Figure 7E, 30 min). Longer incubation with IFN-α,
however, increased the level of Stat2 significantly. The
nuclear level of Stat2 increased up to 12 h after stimulation
and remained at this level for at least 24 h (data not
shown). This result is in agreement with previously
published observations that Stat2 mRNA is induced upon
IFN-α stimulation (Schindler et al., 1992). The quantitative
increase in Stat2 and corresponding time of IFN-α incuba-
tion correlated with the requirement for pre-incubation to
inhibit RelA transactivation (Figure 7A). We therefore
conclude that pre-incubation with IFN-α was indeed
necessary to accumulate sufficient nuclear Stat2 for com-
petition with RelA.
p300 is limiting relative to cytokine-induced RelA
and Stat2 in the nucleus
For competitive binding of RelA and Stat2 to occur in vivo,
it would be necessary that these transcription factors be
present in a high molar excess relative to p300/CBP family
members. To determine whether p300 is limiting relative
to these transcription factors, we quantitated the number
of p300, RelA and Stat2 molecules per cell nucleus after
appropriate cytokine stimulation. Immunoprecipitations
were performed for p300 from unstimulated nuclear
extracts, for RelA from TNF-α-stimulated extracts, or for
Stat2 from IFN-α-stimulated extracts. Different dilutions
of these immunoprecipitated proteins were then compared
with a dilution of known protein standards with the same
slope on silver-stained SDS–PAGE (Figure 8, legend) and
with a defined number of cell equivalents of nuclear
extract by Western blot analysis (Figure 8A–C). Immuno-
fluorescence analysis suggested that the amounts of these
transcription factors per cell is uniform in the cell popula-
tion, and these proteins are found primarily in the nuclear
fraction in the relevant cytokine-stimulated cells (data not
shown). Thus, comparison of silver staining allowed an
estimation of the number of molecules of each immuno-
precipitated protein, and Western blot analysis of nuclear
extracts from a specified number of cells provided a
method to convert this quantity into the number of
molecules per cell nucleus. No substantial difference was
observed in the quantity of nuclear p300 in unstimulated
or stimulated cells (Figure 4A). This quantification docu-
mented that p300 is limiting in the cell nucleus relative
to either RelA or Stat2 after stimulation of cells with
TNF-α or IFN-α, respectively (Figure 8). The observed
difference is ~5-fold, and thus explains the inhibitory
effect of cytokine-induced Stat2 on the transcriptional
activation of NF-κB. Given the significant increase in
levels of these transcriptional factors and apparent lack of
increase in p300/CBP family members in response to
cytokine treatment, it is likely that competition for a
limiting amount of p300/CBP family members is respons-
ible for this effect.
Discussion
Cellular activation by multiple cytokines leads to activation
of multiple signal transduction pathways. The appropriate
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Fig. 7. IFN-α inhibits TNF-α induced HIV-1 gene expression in a dose-dependent manner, and quantitation of Stat2 induction by IFN-α. (A) IFN-α
inhibits κB-dependent gene activation in a dose-dependent manner. Jurkat T-leukemia cells were transfected with HIV–CAT (d, 5 μg) or ΔκB HIV–
CAT (j, 5 μg) and pre-stimulated with the indicated amounts of IFN-α for 20 h followed by TNF-α stimulation (20 U/ml) for 4 h. (B) IFN-α
activates the α-IRE–CAT in a dose-dependent manner. Jurkat T-leukemia cells were transfected with α-IRE–CAT (4 μg) and stimulated with the
indicated amounts of IFN-α for 20 h. (C) 1G5 cells were pre-stimulated with the indicated amounts of IFN-α for 20 h followed by TNF-α
stimulation (20 U/ml) for 4 h. Inhibition is defined relative to the level of inhibition observed with maximal concentrations of IFN-α (105 U/ml).
Maximal IFN-α inhibition corresponded to a 50% inhibition of TNF-α-induced gene expression. Error bars indicate SEM of three independent
experiments. (D) Time course analysis of IFN-α pre-treatment. Jurkat T-leukemia cells were transfected with HIV–CAT (5 μg) and pre-stimulated
with 1000 U/ml IFN-α for the indicated times, followed by TNF-α stimulation (20 U/ml) for 4 h. (E) IFN-α induces nuclear translocation of Stat2
over 24 h. Jurkat cells (5.8107) were simulated with 1000 U/ml IFN-α for different times as indicated and 20 μg of nuclear extract from each time
interval was used for Western blot analysis of Stat2. Signals from the Western blot were quantitated using the ImageQuant program for the indicated
time intervals.
coordination of these regulatory signals is essential both
for viral replication and for cell function/survival. In this
study, we show that TNF-α stimulation of HIV gene
expression by NF-κB in Jurkat T-leukemia cells is inhibited
by IFN-α but not by IFN-γ. The inhibition was specific
for NF-κB, indicating that basal transcriptional regulatory
proteins or other regions of the promoter were not involved.
The inhibition occurred through a novel mechanism
involving the competition for binding of two specific
transcription factors, Stat2 and RelA, to the CH1 region
of p300. A direct or indirect interaction between RelA and
Stat2 was excluded by performing immunoprecipitations
in vitro and in vivo. The identification of p300 as an
integral component of the activation complex for IFN-α-
and TNF-α-released transcription factors and the competi-
tion model for limiting amounts of p300 is strengthened
further by the finding in vivo that overexpression of
p300 was able to abolish Stat2 repression of RelA. The
competition model was also supported by quantification
of the relative molar amounts of p300, RelA and Stat2 in
the nucleus after cytokine induction.
It has been known for some time and was recently
reported that squelching effects caused by transactivator
overexpression using transient transfection experiments
can be misleading (Natesan et al., 1997). To confirm the
specificity of inhibition by transactivators in this present
study, we analyzed these effects in three different ways.
First, a reporter gene without the relevant cis-acting
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regulatory sequences showed no inhibition in the presence
of IFN-α-induced transcription factors or with co-trans-
fected GAL4–Stat2 (Figures 2B, and 6B and D). Secondly,
the inhibitory effects of Stat2 could be restored specifically
by transfection of a vector encoding the full-length p300
coactivator or a deletion mutant expressing the CH1
domain (Figure 6C and D). Thirdly, these effects were
confirmed using a stable integrated reporter gene under
control of the same HIV regulatory region (Figure 7C).
Finally, inhibition was seen with endogenous transcription
factors induced by cytokines.
The possibility that p300/CBP could be a limiting factor
for the integration of multiple signal transduction pathways
had been suggested as a possible mechanism to explain
inhibition of Ap1-dependent gene activation by steroid
receptors and Stat1 (Kamei et al., 1996; Horvai et al.,
1997), but quantitation and competitive binding have not
been demonstrated previously. The competition between
RelA and Stat2 for p300 binding supports this hypothesis
and establishes that such a mechanism is used to regulate
transcription, based on differential recruitment of p300-
and CBP-containing coactivator complexes. Though it
remains possible that TNF-α or IFN-α may modify p300
differentially and affect its ability to bind cytokine-induced
transcription factors, the amount of p300 available for
binding to the relevant transcription factor would remain
rate limiting.
TNF-α has been shown to exert a cytotoxic effect on
Competitive binding of RelA and Stat2 to p300
Fig. 8. Quantitative analysis of nuclear p300, RelA and Stat2. Determination of the molar ratios between p300, RelA and Stat2 in the nucleus. Jurkat
cells (8.7107) were left unstimulated or stimulated with 1000 U/ml IFN-α for 18 h or 100 U/ml TNF-α for 4 h. The number of molecules in the
immunoprecipitations was determined by comparing the signal intensity of immunoprecipitated protein from 200 μg of nuclear extract with standards
on a silver-stained SDS–PAGE. For p300, the comparison was made with 50, 100, 300, 500 and 750 ng of myosin H-chain (A); for RelA after
stimulation with TNF-α, with 10, 50, 100, 300 and 500 ng of phosphorylase B (B); and for Stat2 after stimulation with IFN-α, with 10, 50, 100, 300
and 500 ng of phosphorylase B (C). IP indicates the amount of proteins obtained by using 200 μg of nuclear extract for the immunoprecipitations.
Different dilutions of IP were analyzed for a better analysis (data not shown). The slope of silver-stained RelA protein was 1.51 in comparison with
1.46 for phosphorylase B, 1.09 for Stat2 in comparison with 1.12 for phosphorylase B and 0.81 for p300 in comparison with 0.94 for myosin
H-chain. Equal amounts of immunoprecipitated proteins were then compared in a Western blot analysis with 2, 5, 10, 20 and 40 μg of nuclear
extract from a known number of cells. Numbers of molecules per cell were obtained by dividing the numbers of molecules in the
immunoprecipitates by the number of cells producing the same signal intensity.
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tumor cells (Carswell et al., 1975; Havell et al., 1988).
In several cell types, where TNF-α alone cannot induce
apoptosis, the apoptotic response can be activated when
NF-κB function is absent or inhibited (Beg and Baltimore,
1996; van Antwerp et al., 1996; Wang et al., 1996). The
finding that IFN-α may inhibit specifically the action of
NF-κB in TNF-α-stimulated cells raises the possibility
that it may block the anti-apoptotic effects of NF-κB in
malignant cells and improve the efficacy of its anti-
tumor effect. In complex cellular promoters where other
important cytokine-responsive elements may direct a more
intricate pattern of regulation, the combined effects of
IFN-α and TNF-α may not always lead to transcriptional
inhibition because these cytokines subsequently could
induce other transcription factors which would result in
gene activation. Synergy might thus be expected on
some promoters, while competitive interaction would be
expected for those that are primarily κB- or Stat2-depend-
ent as shown here for the HIV LTR.
A number of studies have investigated the effect of
IFN-α on HIV-1 replication. This inhibitory effect has
been demonstrated in peripheral blood mononuclear cells,
T lymphoblast and monocytoid cell lines (Hartshorn et al.,
1987; Gendelman et al., 1990a; Kornbluth et al., 1990;
Brinchmann et al., 1991; Shirazi and Pitha, 1992). IFN-α
has been shown to affect different steps of the HIV-1
replication cycle, including events prior to integration
(Gendelman et al., 1990b; Meylan et al., 1993; Baca-Regen
et al., 1994), and transcriptional or post-transcriptional
controls (Poli et al., 1989; Smith et al., 1991; Popik and
Pitha, 1992; Coccia et al., 1994; Agy et al., 1995; for
review see Pitha, 1991). Transcriptional inhibition of the
HIV replication life cycle by competitive binding of
transcription factors provides an additional mechanism to
explain the inhibition of HIV-1 gene expression by IFN-α.
Negative regulation of NF-κB by IFN-α through its
coactivators could explain its ability to inhibit HIV tran-
scription in Jurkat T-leukemia cells and hence may partly
contribute to its decrease in replication. Our observation
is in agreement with previous findings that IFN-α can
inhibit HIV transcriptional activation by phorbol esters
in a cell line containing a Tat-defective provirus. Co-
transfection of a Tat expression plasmid into this cell line
not only activated transcription of the provirus but also
overcame the inhibitory effect of IFN-α on transcription
(Popik and Pitha, 1992). Taken together, these results
suggest that Tat may help to overcome transcriptional
inhibition by IFN-α.
In many signal transduction pathways, interactions
between signaling protein kinases and phosphatases modu-
late effects induced by divergent cytokine receptors. In
the case of IFN-α and JAK/STAT signaling, the Stat
transcription factor transduces information from a specific
receptor into the nucleus (Darnell et al., 1994; Shuai et al.,
1994; Schindler and Darnell, 1995; Qureshi et al., 1996)
of Stat by kinases from other signaling pathways in the
cytoplasm less likely to occur. Thus, cells may have
evolved other mechanisms to coordinate the response to
divergent signals in the nucleus. Although other transcrip-
tion factors such as CREB, c-Jun, c-Fos, YY1 and c-Myb
have been shown to bind to p300/CBP, these factors
respond to distinct signal transduction pathways and bind
to sites distinct from Stat2 and RelA (Bhattacharya et al.,
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1996; Eckner, 1996; Perkins et al., 1997), suggesting that
their interactions with different regions of p300/CBP are
likely to control their distinct target gene products. At the
same time, it is also likely that these other transcription
factors may show specific competition among themselves
for binding to different sites on p300/CBP through an
analogous mechanism. Thus, p300/CBP could serve to
integrate information from distinct signaling pathways
from different cytokines in order to coordinate the tran-
scriptional regulation of relevant genes. Whether p300
and CBP or other family members such as p400 (Howe
and Bayley, 1992; Lill et al., 1997b) can compensate for
each other can be addressed with genetically deficient cell
lines or mice, which are not yet available. This is likely
to be the case in Rubenstein–Taybi syndrome (Petrij et al.,
1995), where haplo-insufficiency of CBP is the apparent
cause of developmental defects, supporting the idea that
coactivator levels may be rate limiting for cellular gene
expression. Our data suggest, in addition, that the amount
of p300, CBP or p400 is insufficient to compensate
functionally for the limiting amount of coactivator relative
to the two transcription factors RelA and Stat2. The
interaction between these transcription factors and their
coactivators may also play a role in the regulation of other




HIV–CAT, ΔκB HIV–CAT and RSV–CAT have all been described
previously (Gorman et al., 1982; Nabel and Baltimore, 1987; Leung
and Nabel, 1988). OAS–CAT contains the CAT gene regulated by
the 2–5 oligoadenylate synthetase promoter, which was generated
by PCR using primers GGAATTTCCATATGGATCAGGGGAGTGTCT
and CCGGAATTCATTGACAGGAGAGAGAG and genomic DNA
from Jurkat cells. The PCR products were digested with NdeI and
EcoRI and ligated into RSV–CAT, which had been cut with the same
enzymes. α-IRE–CAT was generated by ligating the double-stranded
oligonucleotide TATGAGGAAACGAAACCAGATATCTGAGGAAA-
CGAAACCAG into RSV–CAT that had been cut with NdeI and
EcoRI, which removed the RSV enhancer element. GAS/α-IRE–
CAT was generated by ligating the double-stranded oligonucleotide
TATGAAGTACTTTCAGTTTCATATTACTCTAAGTACTTTCAGTTT-
CATATTACTCTAGAT into α-IRE–CAT that had been cut with NdeI
and EcoRV. RSV–RelA has been described previously (Perkins
et al., 1994a).
The cDNA insert for pGex–p300 (CH1) was generated by PCR using
primers ATGGGATCCATGGGTCAACAGCCAGCCCCG and AGA-
GAATTCTCAATCACCAGCATTTTTGAGGGGGAG and the p300-
encoding template described in Perkins et al. (1997). The PCR products
were digested with BamHI and EcoRI and ligated into pGEX–CD1,
which had been cut with the same enzymes. pGEX–p300 (CH1)
contains amino acid residues 302–422. Bluescript RelA used for in vitro
transcription/translation has been reported previously (Perkins et al.,
1994b). The cDNA of the Stat2 transactivation domain (amino acids
670–851) was obtained by RT–PCR from 0.5 μg of total RNA from
Jurkat cells (Trizol, Gibco-BRL) using oligo(dT) as a primer and reverse
transcriptase (Perking Elmer) using primers GCTAGGTCGAC-
CACCATGGATGAAGCTTTTGGGTGCTAC and CCGGAATTCCTA-
GAAGTCAGAAGGCATCAAG. The RT–PCR products were digested
with SalI and EcoRI and ligated into pBS, which had been cut with the
same enzymes downstream of the T7 promoter.
GST–Stat2(TA) was generated by digesting the RT–PCR products
with SalI and EcoRI and ligated into pGEX–CD1, which had been cut
with XhoI and EcoRI. pGEX–Stat2 contains amino acid residues 670–
851 of Stat2. GST–Stat2(TA)ΔC was generated by digesting GST–
Stat2(TA) with NsiI and EcoRI. Ends subsequently were blunt ended
with T4 polymerase and religated. pGEX–Stat2ΔC contains amino acid
residues 670–768 of Stat2. pGAL4–Stat2(TA) was constructed by cloning
Competitive binding of RelA and Stat2 to p300
a HincII–XbaI fragment from the above described pBS–Stat2 into
pRSVGAL4.1 cleaved with SmaI and XbaI. pGAL4–Stat2(TA) contains
amino acid residues 670–851 of Stat2. pRSVGAL4.1 was constructed
by ligating the promoter of pRc/RSV (Invitrogen) as an SspI–HindIII
fragment into pSG424 that had been cut with SspI–HindIII. pGAL4–
Stat2(TA)ΔC was generated by digesting pGAL4–Stat2(TA) with XcmI
and BamHI. Ends subsequently were blunt ended with T4 polymerase
and religated. pGAL4–Stat2(TA)ΔC contains amino acid residues 670–
768 of Stat2. pCMV–p300 and pCMV–AP plasmids, together with the
GAL–CAT reporter plasmid (pG5E–CAT) and the pSG424 GAL4
expression plasmid, have all been described previously (Lillie and Green,
1989; Sadowski and Ptashne, 1989; Perkins et al., 1997). The deletion
mutant p300 (amino acids 1–596) and the deletion mutant p300 (amino
acids 1–349) were generated by digesting pCMV-p300 with BamHI and
XbaI or SphI and XbaI. Ends subsequently were blunt ended with T4
polymerase and religated.
Transfections and reporter assays
Jurkat T-leukemia cells were transfected using DEAE-dextran, cells were
harvested after 24 h, and CAT assays were performed as previously
described (Leung and Nabel, 1988). RelA transfection of 293 cells was
performed as described previously (Perkins et al., 1997). Cells were
stimulated with either TNF-α (Genzyme) or IFN-α (Referone-A, Roche)
as indicated. Luciferase activity was measured according to Aguilar-
Cordova et al. (1994).
Electrophoretic mobility shift assays
Nuclear extracts were prepared and analyzed by EMSA for κB binding
activity as described previously (Shu et al., 1993; Perkins et al., 1994a).
Cells were harvested and nuclear extracts (5 μg) were analyzed using a
32P-labeled double-stranded κB oligonucleotide probe. Unlabeled wild-
type and mutant competitor DNAs (20 ng) were included as indicated.
Protein binding assays and Western blots
RelA immunoprecipitations of 293 cells were performed as described
previously (Perkins et al., 1997) with 1 μg of an anti-RelA antibody
(Santa Cruz #sc109) or control rabbit IgG. Deletion analysis of the
N-terminal fragments of p300 was performed by digesting pBS–p300
(Perkins et al., 1997) with ScaI, NdeI or SphI, prior to in vitro
transcription/translation (radiolabeled T7 TNT reticulocyte transcription/
translation system, Promega) to produce p300 fragments truncated at
amino acids 1031, 610 or 347, respectively. RelA and Stat2 immunopre-
cipitations of Jurkat cells were performed with 1.5 μg of an anti-RelA
antibody (Santa Cruz #sc109), an anti-Stat2 antibody (Santa Cruz #sc476)
or control rabbit IgG. GST–CH1 was expressed and purified as reported
(Smith and Johnson, 1988). Beads containing fusion proteins sub-
sequently were incubated with the indicated radiolabeled TNT rabbit
reticulocyte proteins. Purified GST was used as the control. p300
immunoprecipitations were performed as described previously (Perkins
et al., 1997) with 1 μg of an anti-p300 antibody (PharMingen #14991A)
or control rabbit IgG in the presence of 250 mM NaCl to eliminate
binding of associated endogenous factors (such as RelA, Stat2, Cdk2,
cyclin E). Beads containing p300 subsequently were pre-incubated with
GST–Stat2(TA) (1 μg) or GST–Stat2(TA)ΔC (1 μg) for 30 min at 4°C,
in the presence of 75 mM NaCl, followed by an incubation with
radiolabeled in vitro translated RelA for 2 h at 4°C. The assay was
terminated by the addition of SDS gel loading buffer to the samples.
Samples were resolved on a 10% SDS–polyacrylamide gel, which was
then dried and subjected to autoradiography. Western blot analysis was
performed as described (Perkins et al., 1997) using anti-p300 antibody
(Santa Cruz #sc584 and #sc585), anti-RelA antibody (Santa Cruz #sc109)
and anti-Stat2 antibody (Santa Cruz #sc476 and #sc839).
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